Created at	Source	Raw Value	Validated value
June 3, 2022, 2 p.m.	usa	Adult Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19);Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specified Time Points;Pediatric Expansion: Deaths Due to Any Cause;Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Specified Time Points;Pediatric Expansion: Incidence and Severity of AESIs Attributed to Study Vaccine Through Specified Time Points until Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points until Month 24;Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49;Pediatric Expansion: Incidence and Severity of SAEs Attributed to Study Vaccine Through Specified Time Points until Month 24;Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Specified Time Points;Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49;Pediatric Expansion: Reactogenicity Incidence and Severity	Adult Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19);Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specified Time Points;Pediatric Expansion: Deaths Due to Any Cause;Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Specified Time Points;Pediatric Expansion: Incidence and Severity of AESIs Attributed to Study Vaccine Through Specified Time Points until Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points until Month 24;Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49;Pediatric Expansion: Incidence and Severity of SAEs Attributed to Study Vaccine Through Specified Time Points until Month 24;Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Specified Time Points;Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49;Pediatric Expansion: Reactogenicity Incidence and Severity
Dec. 2, 2021, 11:30 p.m.	usa	Adult Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19);Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points;Pediatric Expansion: Deaths Due to Any Cause;Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12;Pediatric Expansion: Incidence and Severity of AESIs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12;Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49;Pediatric Expansion: Incidence and Severity of SAEs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12;Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49;Pediatric Expansion: Reactogenicity Incidence and Severity	Adult Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19);Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points;Pediatric Expansion: Deaths Due to Any Cause;Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12;Pediatric Expansion: Incidence and Severity of AESIs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12;Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49;Pediatric Expansion: Incidence and Severity of SAEs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12;Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49;Pediatric Expansion: Reactogenicity Incidence and Severity
April 30, 2021, 7:54 a.m.	usa	Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19);Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points;Pediatric Expansion: Deaths Due to Any Cause;Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12;Pediatric Expansion: Incidence and Severity of AESIs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12;Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49;Pediatric Expansion: Incidence and Severity of SAEs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12;Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49;Pediatric Expansion: Reactogenicity Incidence and Severity	Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19);Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points;Pediatric Expansion: Deaths Due to Any Cause;Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12;Pediatric Expansion: Incidence and Severity of AESIs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12;Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49;Pediatric Expansion: Incidence and Severity of SAEs from Month 12 to Month 24;Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12;Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49;Pediatric Expansion: Reactogenicity Incidence and Severity
Nov. 3, 2020, 11:31 p.m.	usa	Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)	Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)